As new protocols have recently become available for treating pediatric and older adolescent/young adult patients with acute lymphoblastic leukemia (ALL), new challenges and opportunities have developed. Data have emerged that have implications for treatment selection and application in these patient populations, especially regarding the role of asparaginases.
For those interested in learning more about navigating this changing landscape, a talk show-style program supported by Servier entitled, “New Data and Paradigms in ALL: Insights and Applications,” will be held at 12:30pm ET on December 6, 2019 at the Hyatt Regency Orlando prior to 61st ASH Annual Meeting and Exposition.
This interactive symposium aims to educate hematologists/oncologists on how to apply data on new and emerging therapies and protocols, including the use of asparaginase-containing regimens, to optimize, manage and achieve the best outcomes for patients, with a focus on how the latest data can guide tailoring of treatment for individual patients.
The faculty will describe and discuss the very latest data and thinking in the treatment of ALL across the full spectrum of age groups encountered in practice: pediatrics, adolescents/young adults and adults. Audience members will be able to submit questions to faculty for discussion during the Q&A session.
The top 2 learning objectives are to increase knowledge regarding the new data on emerging treatments and protocols in ALL, and their implications for routine practice; and to develop greater competence related to selecting the right treatment protocol for the individual patient with ALL, as well as selecting, optimizing, and applying asparaginase-containing regimens for individual patients and managing associated side effects and hypersensitivity/silent inactivation.
The session will be moderated by Daniel J. DeAngelo, MD, PhD., Professor of Medicine, Harvard Medical School Physician, Adult Leukemia Program. Dana-Farber Cancer Institute (Boston, Massachusetts)
The speakers featured in the program that is designed to improve the knowledge and confidence of hematologists/oncologists in applying best practice in the treatment of ALL are:
- Dan Douer, MD, Associate Professor of Medicine, Division of Hematology School of Medicine, Director, Bone Marrow Transplantation Program, USC/Norris Comprehensive C Cancer Center (Los Angeles, California)
- Lewis B. Silverman, MD, Director, Clinical Research and Clinical Care Pediatric Oncology, Dana-Farber Cancer Institute (Boston, Massachusetts)
- Wendy Stock, MD, Professor of Medicine Hematology/Oncology, Anjuli Seth Nayak Professor of Leukemia Research. University of Chicago Medicine (Chicago, Illinois)
Among the topics to be discussed are:
- 1:05 PM “New Protocols for Older Adolescents/Young Adults with ALL: What Are the Implications for Practice?” with DeAngelo and Stock
- 1:30 PM “Selecting and Applying Asparaginases for Pediatric and AYA Protocols: What’s New?” with DeAngelo and Silverman
- 1:55 PM “Evolving Best Practices in Adults With ALL: What Can We Do Better?” with DeAngelo and Douer
- 2:20 PM “Panel Discussion and Question & Answer Session” with moderator DeAngelo and panelists Douer, Silverman, and Stock.
ASH attendees are encouraged to register here to attend the symposium.
Physicians attending will be eligible for 1.5 professional credits. Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, Medscape is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.